Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for the majority of Israel's hospital-based translational research.
The HBL traded stock, as a unique investment vehicle, provides investment exposure to a select portfolio of 6 biotech companies - all based on inventions developed and owned by Hadassah. The companies operate in the fields of Oncology (Rx and Dx), Regenerative Medicine and Inflammatory Disease.
HBL focuses on funding the preparation for and execution of Phase I and preparation for Phase II by the portfolio companies. Preparations include pre-clinical trials, manufacturing, regulatory and business development tasks.
HBL utilizes a competitive advantage symbolized as triple “ I " : I nnovation, I nfrastructure & I nvestment.
   
| 
